Aileron Therapeutics, Inc. (ALRN) financial statements (2022 and earlier)

Company profile

Business Address 285 SUMMER STREET
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments45,93313,80518,27820,69550,752
Cash and cash equivalents3,6007,0465,31110,63511,863
Short-term investments42,3336,75912,96710,06038,889
Restricted cash and investments25593252588
Other undisclosed current assets2,2191,9281,2471,0551,000
Total current assets:48,17716,32619,55021,77551,840
Noncurrent Assets
Operating lease, right-of-use asset152 6,060
Property, plant and equipment128152957,290154
Restricted cash and investments  568568 
Other noncurrent assets24  679694
Total noncurrent assets:304156,9238,537848
TOTAL ASSETS:48,48116,34126,47330,31252,688
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,7802,6533,3683,6403,256
Accounts payable1,2101,5961,4521,7311,600
Accrued liabilities388135635436536
Employee-related liabilities1,1829221,2811,4731,120
Debt  446  
Other undisclosed current liabilities1,7281,3072,0251,7301,635
Total current liabilities:4,5083,9605,8395,3704,891
Noncurrent Liabilities
Long-term debt and lease obligation69 4,5865,342 
Long-term debt, excluding current maturities   5,342 
Operating lease, liability69 4,586
Other undisclosed noncurrent liabilities(69)219   
Total noncurrent liabilities:692194,5865,342 
Total liabilities:4,5774,17910,42510,7124,891
Stockholders' equity
Stockholders' equity attributable to parent43,90412,16216,04819,60047,797
Common stock9144281515
Additional paid in capital289,282231,412214,148188,083184,761
Accumulated other comprehensive income (loss)(13)(2)7(5)(33)
Accumulated deficit(245,456)(219,292)(198,135)(168,493)(136,946)
Total stockholders' equity:43,90412,16216,04819,60047,797
TOTAL LIABILITIES AND EQUITY:48,48116,34126,47330,31252,688

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(26,605)(20,496)(29,956)(31,902)(23,008)
Operating loss:(26,605)(20,496)(29,956)(31,902)(23,008)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
441(661)   
Loss before gain (loss) on sale of properties:(26,164)(21,157)(29,956)(31,902)(23,008)
Other undisclosed net income  587355 
Net loss:(26,164)(21,157)(29,369)(31,547)(23,008)
Other undisclosed net income attributable to parent    404
Net loss attributable to parent:(26,164)(21,157)(29,369)(31,547)(22,604)
Preferred stock dividends and other adjustments    (41)
Net loss available to common stockholders, diluted:(26,164)(21,157)(29,369)(31,547)(22,645)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(26,164)(21,157)(29,369)(31,547)(23,008)
Comprehensive loss:(26,164)(21,157)(29,369)(31,547)(23,008)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(11)(9)1228371
Comprehensive loss, net of tax, attributable to parent:(26,175)(21,166)(29,357)(31,519)(22,637)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: